Cardiovascular Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)
Verified date | October 2012 |
Source | Stratum Nutrition |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Cardiovascular diseases (CVDs), especially atherosclerotic coronary heart disease and stroke, are the leading causes of death globally. Important risk factors for CVDs include elevated serum levels of total cholesterol, low-density lipoprotein(LDL)-cholesterol, triglycerides, and low high-density lipoprotein (HDL)-cholesterol. Elevated "oxidized" LDL, a pro-inflammatory villain, has also emerged as an important risk factor for the development of CVDs. There is a growing need to identify safe and effective nutritional interventions that offer a clinical benefit aimed at reducing one more of the risk factors for CVDs. Data from many studies in humans have shown various health benefits provided by dietary fiber intake, including an inverse association with the risk of developing cardiovascular disease. The primary purpose of this study is to determine whether daily consumption for 6 weeks of chitin-glucan, a fiber purified from a microorganism, is effective at reducing the amount of oxidized LDL in humans with borderline-to-high LDL-cholesterol. The effects of chitin-glucan on other cardiovascular risk factors will also be evaluated.
Status | Completed |
Enrollment | 135 |
Est. completion date | January 2011 |
Est. primary completion date | January 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 21 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Male or female able to read, comprehend, and write English at sufficient level to complete study-related materials including informed consent 2. Age: 21 - 70 years 3. Body Mass Index: 18.5 - 34.9 kg/m2 4. Fasting serum LDL-cholesterol: = 130 - 189.9 mg/dl 5. Willing to take supplement three times daily for 6 weeks and undergo other study-related procedures 6. Is otherwise is in general good health as determined by the principal investigator Exclusion Criteria: 1. Known hypersensitivity or intolerance to fiber or fiber-containing products 2. Use of any investigational drugs prior to Visit 1 3. Participation in any clinical trial while participating in this trial 4. Member or family member of research staff or study sponsor involved in the conduct of this trial 5. Greater than 5% change in body weight within 1 month of Visit 1 6. Positive pregnancy test 7. Is taking lipid-altering drug therapy within four weeks prior to Visit 1. Also excluded are supplements known to have significant lipid altering effects, such as niacin (>100 mg per day), garlic (> 600 mg per day), omega-3 fatty acids (> 1 g omega-3 fatty acids per day), red yeast rice extract, phytostanols / phytosterols (> 0.5 g per day), soluble fiber (>1 g per day), chitosan (> 1 g per day) and conjugated linoleic acid (CLA; > 3 g per day) 8. Excluded concurrent medications are: systemic corticosteroids (nasal and inhaled corticosteroids are permitted), orlistat, bile acid resins, no more than 1 g of prescription omega-3 fatty acids, cyclical or non-continuous hormone therapy (estrogen or testosterone) 9. No more than 2 units of ethanol per day. Units are defined as 1.5 ounces of 80 proof alcohol per day, e.g. 2 twelve ounce cans of beer per day. 10. Has a fasting serum triglyceride > 300 mg/dl 11. Has a diagnosis of type 1 or type 2 diabetes mellitus or fasting glucose > 126 mg/dl 12. Has a serum thyroid-stimulating hormone (TSH) higher than 1.5 times the upper limit of normal for the laboratory 13. Is breast feeding, pregnant, or planning on becoming pregnant during the duration of the study 14. Known cardiovascular disease or stroke, except for conditions that are deemed clinically insignificant by Principle Investigator or Sub-investigator, or study site physician (e.g. clinically insignificant atherosclerotic lesions observed by imaging studies). 15. History of significant gastrointestinal disease such as severe constipation, diarrhea, malabsorptive disease, inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis) 16. History of severe psychiatric illness which in the opinion of the investigator would interfere with the optimal participation in the study 17. History if cancer within 5 years of Visit 1 (except for successfully treated basal and squamous cell carcinoma of the skin) 18. Known human immunodeficiency virus (HIV) seropositivity 19. History of bariatric surgery 20. Aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3 times the upper limit of normal 21. Creatine kinase (CK) = 3 times the upper limit of normal, unless explained by recent physical activity or trauma; or > 5 times the upper limit of normal, irrespective of circumstance 22. Creatinine = 1.5 mg/dl 23. Individuals who in the opinion of the principal investigator have a risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trail |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Canada | KGK Synergize | London | Ontario |
United States | Provident Clinical Research and Consulting | Addison | Illinois |
United States | Louisville Metabolic and Atherosclerosis Research Center (L-MARC) | Louisville | Kentucky |
Lead Sponsor | Collaborator |
---|---|
Stratum Nutrition | Kitozyme |
United States, Canada,
Anderson JW, Baird P, Davis RH Jr, Ferreri S, Knudtson M, Koraym A, Waters V, Williams CL. Health benefits of dietary fiber. Nutr Rev. 2009 Apr;67(4):188-205. doi: 10.1111/j.1753-4887.2009.00189.x. Review. — View Citation
Bays HE, Evans JL, Maki KC, Evans M, Maquet V, Cooper R, Anderson JW. Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial. Eur J Clin Nutr. 2013 Jan;67(1):2-7. doi: 10.1038/ejcn.2012.121. Epub 2012 Sep 5. — View Citation
Berecochea-Lopez A, Decordé K, Ventura E, Godard M, Bornet A, Teissèdre PL, Cristol JP, Rouanet JM. Fungal chitin-glucan from Aspergillus niger efficiently reduces aortic fatty streak accumulation in the high-fat fed hamster, an animal model of nutritionally induced atherosclerosis. J Agric Food Chem. 2009 Feb 11;57(3):1093-8. doi: 10.1021/jf803063v. — View Citation
Huang H, Mai W, Liu D, Hao Y, Tao J, Dong Y. The oxidation ratio of LDL: a predictor for coronary artery disease. Dis Markers. 2008;24(6):341-9. — View Citation
Jonker D, Kuper CF, Maquet V, Nollevaux G, Gautier S. Subchronic (13-week) oral toxicity study in rats with fungal chitin-glucan from Aspergillus niger. Food Chem Toxicol. 2010 Oct;48(10):2695-701. doi: 10.1016/j.fct.2010.06.042. Epub 2010 Jun 30. — View Citation
Neyrinck AM, Possemiers S, Verstraete W, De Backer F, Cani PD, Delzenne NM. Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. J Nutr Biochem. 2012 Jan;23(1):51-9. doi: 10.1016/j.jnutbio.2010.10.008. Epub 2011 Mar 15. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Oxidized LDL | After 4 and 6 weeks | No | |
Secondary | Total cholesterol | After 4 and 6 weeks | No | |
Secondary | LDL-cholesterol | After 4 and 6 weeks | No | |
Secondary | HDL-cholesterol | After 4 and 6 weeks | No | |
Secondary | Triglycerides | After 4 and 6 weeks | No | |
Secondary | Glucose | After 4 and 6 weeks | No | |
Secondary | Insulin | After 4 and 6 weeks | No | |
Secondary | F2-isoprostanes (urine) | After 4 and 6 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236337 -
Effectiveness of MOVI Interventions on Adiposity, Cognition and Subclinical Atherosclerosis: MOVI-daFit!
|
N/A | |
Completed |
NCT03236363 -
Effectiveness of MOVI Interventions on Adiposity, Cognition and Motor Competence: MOVI-da10!
|
N/A | |
Completed |
NCT01304641 -
Cardiovascular Events Based On Statin Initiation In The Elderly
|
||
Terminated |
NCT03277183 -
Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin
|
Phase 4 | |
Not yet recruiting |
NCT05316025 -
Cardiovascular Digital Health Data Observatory
|
||
Completed |
NCT03170193 -
AMG 529 First in Human Study
|
Phase 1 | |
Recruiting |
NCT05775484 -
Exercise to Slow Cardiovascular Ageing Progression
|
||
Active, not recruiting |
NCT05085275 -
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT04863040 -
The Impact of Activity Breaks on Cognitive Function, Adiposity and Fitness in Preschoolers
|
N/A | |
Not yet recruiting |
NCT04866732 -
Physical Activity Program for Cardiac Health Among Older African American Populations
|
N/A | |
Recruiting |
NCT05568966 -
Collection of Blood Samples for New Diagnostic Devices 2
|
N/A | |
Recruiting |
NCT01820598 -
Phase II Study of Neuromuscular Electrical Multisite System on Cardiovascular Effects in Severe Obese Patients
|
N/A | |
Completed |
NCT00824330 -
Home-Based Walking Study in Older Adults With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06238466 -
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
|
Phase 1 | |
Completed |
NCT00387452 -
Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05249296 -
The Impact of Green Spaces on the General Well-being and Stress of Students
|
N/A | |
Completed |
NCT01489696 -
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
|
Phase 1 | |
Completed |
NCT00954902 -
Effects of Antioxidants on Cardiovascular Risk Measures (Spice Study)
|
N/A | |
Completed |
NCT04216238 -
Association of Wearable Activity Monitors With Post-Operative Activity Level Among Cardiovascular Surgical Patients
|
||
Completed |
NCT04121416 -
Comparison of Effects of Oxycodone and Sufentanil on Cardiovascular Stress Induced by Tracheal Intubation in the Patients With Coronary Heart Disease Undergoing Major Noncardiac Surgery
|
N/A |